Prof. Robert
Sutton to deliver plenary presentation on Phase
2b CARPO trial of Auxora™ in Acute
Pancreatitis (AP) at American Pancreatic Association (APA)
2024 Annual Meeting
Poster presentation on Phase
2b CARPO trial at Emergencies
in Medicine (EIM) 2024 Meeting
LA
JOLLA, Calif., Nov. 20,
2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica")
(Nasdaq: CALC), a clinical-stage biopharmaceutical company focused
on developing novel calcium release-activated calcium (CRAC)
channel inhibition therapies for acute and chronic inflammatory and
immunologic illnesses, today announced the acceptance of an
abstract for plenary presentation at the American Pancreatic
Association (APA) 2024 Annual Meeting being held December 9-10 in Maui,
HI, and the acceptance of an abstract for poster
presentation at the Emergencies in Medicine (EIM) 2024 Meeting
being held December 8-13 in
Maui, HI.
Details for the presentations are as follows:
Plenary Presentation at APA 2024 Annual Meeting
Presentation Title: Auxora Decreases the Development of
Severe Organ Failure in Patients with Acute Pancreatitis and
SIRS
Presenter: Prof. Robert
Sutton, B.A. (Hons), M.B., B.S., D.Phil., FRCS, University of Liverpool and Liverpool University Hospitals NHS Foundation
Trust
Session Title: Abstract Session 2 –
Pancreatitis
Session Date and Time: Tuesday,
December 10, 8:00-9:30 a.m.
HST
Poster Presentation at EIM 2024 Meeting
Presentation Title: A Randomized, Double-Blind, Placebo
Controlled Dose Ranging Study of Auxora in Patients with Acute
Pancreatitis (AP) and Accompanying Systemic Inflammatory Response
Syndrome (SIRS)- CARPO (NCT0468106)
The presentation and poster will be available following the
sessions on the Medical Events & Presentations section of
CalciMedica's IR website at
https://ir.calcimedica.com/news-events/medical-events-publications.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic
diseases. CalciMedica's proprietary technology targets
the inhibition of CRAC channels to modulate the immune response and
protect against tissue cell injury, with the potential to provide
therapeutic benefits in life-threatening inflammatory and
immunologic diseases for which there are currently no approved
therapies. CalciMedica's lead product candidate Auxora™
has demonstrated positive and consistent clinical results in
multiple completed efficacy clinical trials. CalciMedica has
announced topline data for a Phase 2b
trial (called CARPO – NCT04681066) in patients with acute
pancreatitis (AP) and accompanying systemic inflammatory response
syndrome (SIRS) and completed a Phase 2 trial (called CARDEA
– NCT04345614) in patients with COVID pneumonia. The Company
is currently conducting a Phase 2 trial (called KOURAGE
– NCT06374797) in patients with acute kidney disease (AKI)
with associated acute hypoxemic respiratory failure (AHRF) with
data expected in 2025 and continuing to support the ongoing Phase
1/2 trial (called CRSPA – NCT04195347) in pediatric patients
with asparaginase-induced pancreatic toxicity (AIPT) with data
expected in 2025. CalciMedica was founded by scientists
from Torrey Pines Therapeutics and the Harvard CBR Institute
for Biomedical Research, and is headquartered in La Jolla,
CA. For more information, please
visit www.calcimedica.com.
Forward-Looking Statements
This communication contains
forward-looking statements which include, but are not limited
to, CalciMedica's ongoing and planned clinical trials and the
timing, design, expected patient enrollment thereof and the
expected timing for the release of data from those trials,
including its Phase 2b CARPO trial of
Auxora for AP with accompanying SIRS, its ongoing Phase 1/2 CRSPA
trial of Auxora in pediatric patients with AIPT, and its planned
Phase 2 KOURAGE trial of Auxora in AKI with associated AHRF; the
potential benefits of Auxora for the treatment of AP, AKI and AIPT;
and the potential of CalciMedica's proprietary technology to
provide therapeutic benefits in life-threatening inflammatory and
immunologic diseases. These forward-looking statements are subject
to the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. CalciMedica's expectations and
beliefs regarding these matters may not materialize. Actual
outcomes and results may differ materially from those contemplated
by these forward-looking statements as a result of uncertainties,
risks, and changes in circumstances. Risks and uncertainties that
could cause actual outcomes and results to differ materially from
those contemplated by the forward-looking statements are included
under the caption "Risk Factors" in CalciMedica's Annual Report on
Form 10-K for the year ended December
31, 2023, and elsewhere in CalciMedica's subsequent
reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from
time to time and available at www.sec.gov. These documents can be
accessed on CalciMedica's web page at
ir.calcimedica.com/financials-filings/sec-filings. The
forward-looking statements contained herein are made as of the date
hereof, and CalciMedica undertakes no obligation to update them
after this date, except as required by law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-presentations-at-upcoming-medical-meetings-302312062.html
SOURCE CalciMedica, Inc.
